This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.
<a href="${link:{uuid:{edff588a-de09-4893-a850-fff622441572},repository:{dam},path:{/Portal/UK/Prescribing-links/Admelog.pdf}}}" target="_blank">Prescribing Information (GB only)</a>

<h2>Head-to-head studies Admelog® vs Humalog®</h2>

<h3>Similar PK/PD profile1</h3>
PK/PD profiles in the biosimilar, Admelog, were similar to the EU-approved Humalog in adult males with Type 1 diabetes1

TYPE-2-DIABETES

TYPE-1-DIABETES

DIABETES

<h3>Similar mean HbA1C reduction2,3</h3>
Similar mean HbA1C reduction from baseline to Week 26 in Admelog and Humalog groups, in both Type 1 and Type 2 diabetes2,3

<h3>Similar long-term safety and tolerability profiles2,3</h3>
Similar rates of patients with at least one hypoglycaemic event, regardless of the category, was observed in both Admelog and Humalog groups in Type 1 and Type 2 diabetes2,3

Abbreviations

<a href="/uk/type-2-diabetes">SEE MORE FROM SCIENCE</a>

<h3>Admelog</h3>
Admelog is indicated for the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis and for the initial stabilisation of diabetes mellitus.&nbsp;
This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

<h3>Patient Website</h3>
Find resources and support for your patients on Admelog®. Help patients understand the basics of living and staying well with diabetes and how to have a positive start and experience with the medication prescribed to them.

<h2>Get in touch with the Diabetes Team</h2>

Admelog® (insulin lispro 100 units/mL)
   

Admelog® (insulin lispro 100 units/mL) Prescribing Information (GB only)

Head to Head Studies

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

<a href="${link:{uuid:{62efcdcd-db16-49b4-8041-55c212a401fa},repository:{dam},path:{/Portal/UK/Prescribing-links/Trurapi-PI-GB-April-2023.pdf}}}" target="_blank">Prescribing Information (GB only)</a>

<h2>Head-to-head studies Trurapi®&nbsp;vs NovoRapid®</h2>

<h3>Similar PK/PD profile in adults with T1DM1</h3>
PK/PD profiles in the biosimilar Trurapi®, were similar to the UK and EU-approved NovoRapid®&nbsp;and US-approved Novolog®&nbsp;in patients with T1DM.1&nbsp;

<h3>Similar mean HbA1C&nbsp;reduction in adults with T1DM and T2DM2</h3>
At week 26, HbA1C&nbsp;was -0.38% for Trurapi®&nbsp;group vs -0.30% for NovoRapid®/NovoLog®&nbsp;group. Similar mean HbA1C reduction from baseline to Week 26 in Trurapi®&nbsp;and NovoRapid®/Novolog®&nbsp;groups were observed in patients with either T1DM or T2DM.2

<h3>Similar long-term safety and tolerability profiles in adults with T1DM and T2DM2,3</h3>
Similar incidence rates of any hypoglycaemic events (≥1 event) in both the T1DM and overall population were observed in both Trurapi®&nbsp;and NovoRapid®/Novolog®&nbsp;groups.2,3
For more information and for data from the 6-month safety extension trial, download the clinical summary.&nbsp;

<h2>Want to know more about the bioequivalence data?</h2>

Watch this short video summarising the similar PK/PD profile (T1DM), efficacy, safety and tolerability profile (T1DM and T2DM) in Trurapi® vs. NovoRapid® from two clinical studies in adults.1,2

<a href="/uk/type-1-diabetes">SEE MORE FROM SCIENCE</a>

<h3>Trurapi</h3>
Trurapi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.&nbsp;
This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

<h3>Patient Website</h3>
Find resources and support for your patients on&nbsp;Trurapi®. Help patients understand the basics of living and staying well with diabetes and how&nbsp;to have a positive start and experience with the&nbsp; medication prescribed to them.

Trurapi®▼ (insulin aspart 100 units/mL)  

Trurapi®▼ (insulin aspart 100 units/mL) Prescribing Information (GB only)

<h2> 
 About Pompe disease</h2>
Pompe disease is a rare, progressive, and potentially fatal neuromuscular disease that affects multiple organ systems in the body.3
Also known as acid alpha-glucosidase deficiency, acid maltase deficiency (AMD), and glycogen storage disease type II (GSD-II), Pompe disease is a type of lysosomal storage disease and is characterised by the progressive accumulation of glycogen in muscle cells.2,3

<h3>An estimated 1 in 40,000 people worldwide are living with Pompe disease&nbsp;4–6</h3>

<h2>What causes Pompe disease?</h2>
Pompe disease is a genetic disease, inherited in an autosomal recessive manner, and&nbsp; 
 is caused by dysfunctional or deficient acid alpha-glucosidase (GAA).2,3&nbsp;This is the&nbsp; 
 enzyme responsible for breaking down glycogen in the lysosomes of cells.2

When there is a GAA activity deficiency, glycogen accumulation progressively impairs skeletal, respiratory, and smooth muscle function.2,3
Glycogen accumulation can begin early in the Pompe disease process, before the onset of detectable symptoms, and lead to extensive and irreversible muscle damage.7
This early progression in Pompe disease pathology highlights the importance of early diagnosis and access to disease-specific care.1,5,7 
 &nbsp;

1.&nbsp;Pompe disease starts with a few glycogen-filled lysosomes, a stage where early muscle impairment may not be clinically detectable7

2.&nbsp;As glycogen accumulates, lysosomes expand and start to rupture causing progressive muscle weakness and functional impairment7

3.&nbsp;Increasing cytoplasmic glycogen damages the contractile structure of myofibrils, resulting in the development of more severe symptoms7

<h2>What are the different types of Pompe disease?</h2>
There are two main types of Pompe disease: 1:&nbsp;Late-onset Pompe disease (LOPD) and 2:&nbsp;Infantile-onset Pompe disease (IOPD) &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;
<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td style="background-color: rgb(184, 228, 230);">
 <h3>LOPD</h3></td>
 <td style="background-color: rgb(122, 210, 214);">
 <h3>IOPD</h3></td>
 </tr>
 <tr>
 <td style="background-color: rgb(184, 228, 230);">Symptoms can first present at any age3.&nbsp; &nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</td>
 <td style="background-color: rgb(122, 210, 214);">Onset is typically within the first few months of life 3,8</td>
 </tr>
 <tr>
 <td style="background-color: rgb(184, 228, 230);">Slowly progressive2,3</td>
 <td style="background-color: rgb(122, 210, 214);">Severe and rapid progression3</td>
 </tr>
 <tr>
 <td style="background-color: rgb(184, 228, 230);">GAA enzyme activity is usually between 1% and 40% of normal9&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</td>
 <td style="background-color: rgb(122, 210, 214);">GAA enzyme activity may be completely missing; if some remains, it is usually &lt;1% of normal9</td>
 </tr>
 </tbody>
</table>

LOPD and IOPD differ in terms of prevalence, age of onset, level of GAA enzyme activity, severity, and progression.2,3,4,9
Although there is a crossover of clinical symptoms that are observed in both LOPD and IOPD, there are some key differences.
Cardiac symptoms are often seen early in IOPD, but are rare in people with LOPD.2,8,10
L

To defy the average and reduce the delay in Pompe disease diagnosis start here.1
Learn about the genetic changes that cause the disease, and how these can be inherited within a family.2

POMPE

RARE-DISEASE

What is Pompe disease?

<h2>What is the burden of influenza for at-risk patients?</h2>

Some people may be at increased risk of influenza-related complications, including:1

Adults aged 65 + years

Those with underlying health conditions

Pregnant women

Babies and children

Flu vaccination is an essential part of helping protect communities29

<h2>What are the complications associated with the burden of Influenza?</h2>

<h3>Influenza may trigger other unwanted health complications for patients</h3>
Evidence indicates that influenza may trigger severe cardiovascular complications beyond respiratory infection.7
A self-controlled case series study conducted in Scotland showed that adults aged 40 years and older (median age 68), without a history of heart attack or stroke, were at a significantly increased risk of severe cardiovascular complications in the 1–3 days following a confirmed influenza infection.7

<h3>In the 1–3 days following a laboratory-confirmed influenza infection:a</h3>

Risk of having&nbsp;a heart attack7

Risk of having&nbsp;a stroke7

aIn a self-controlled case series study&nbsp;(based on a population in Scotland 2004-2014) conducted on a database of adults aged ≥ 40 years with ~90% of the study population aged 50 years and older. In the 1–3 days following a laboratory-confirmed influenza infection versus unexpected or baseline time periods.

CI, confidence interval; IR, incidence ratio.

<h2>Hospitalisations and economic burden of influenza</h2>
Influenza has an associated impact on healthcare costs and resources.
Influenza may have a considerable burden on secondary healthcare systems.30

Hospital admissions during the 2018/19 influenza season had associated medical costs of £99,565,310.1&nbsp;The highest costs were found to be associated with patients aged 65+ years.30

Certain groups may create increased pressure as they are more likely to experience a longer and more severe illness. During the 2018/19 influenza season:30

<table cellpadding="20" cellspacing="1" style="width:100%;">
 <tbody>
 <tr>
 <td style="background-color: rgb(122, 0, 230);">&lt;65 years</td>
 <td style="background-color: rgb(122, 0, 230);">
 75+ years</td>
 </tr>
 <tr>
 <td style="background-color: rgb(245, 247, 251);">
 Costs per hospitalisation:&nbsp;~£1,900</td>
 <td style="background-color: rgb(245, 247, 251);">
 Costs per hospitalisation: ~£3,700</td>
 </tr>
 <tr>
 <td style="background-color: rgb(245, 247, 251);">
 Average length of stay: 4.74 days</td>
 <td style="background-color: rgb(245, 247, 251);">
 Average length of stay: 12.55 days</td>
 </tr>
 <tr>
 <td style="background-color: rgb(245, 247, 251);">
 Mortality:&nbsp;1.83%</td>
 <td style="background-color: rgb(245, 247, 251);">
 Mortality:&nbsp;11.18%</td>
 </tr>
 </tbody>
</table>

Every year, millions of cases of influenza are recorded worldwide.

INFLUENZA

VACCINES

Burden of Influenza

At Sanofi, we have a rich history of MS research and treatment dating back to the 1970s. Through our partnership with Cambridge University, we have been at the forefront of delivering breakthrough medications to patients. Our commitment to patients and our passion for innovation in neurological disorders, such as Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and others, remains a top priority and investment for us.
We are driven by the desire to understand the science behind diseases like MS, which motivates us to challenge our assumptions and offer innovative solutions to meet the unmet needs of people affected by these conditions. With ongoing research into various treatments, we invite healthcare professionals to stay tuned for further updates and information later this year!

Thank you for visiting our Neurology page, and we look forward to your continued engagement and collaboration in advancing patient care.

MULTIPLE-SCLEROSIS

NEUROLOGY

Multiple Sclerosis

Prescribing Information can be found through the links in the Product Cards at the bottom of the page

<h3>MAGE: patient satisfaction</h3>
MAGE was a real-world study investigating patient satisfaction in patients with T2D receiving&nbsp;Toujeo®.
There was an improvement of at least 2 points in DTSQ score at Month 6 from baseline, meeting the primary endpoint of the study.2
MAGE was a 6-month, multicentre, prospective, single-arm, observational, real-world study (conducted in Belgium) following 87 people with T2D who had been receiving basal and mealtime insulin for&nbsp;≥6 months.
Primary endpoint: change in DTSQ total score (baseline to Month 6).2
DTSQ: Diabetes Treatment Satisfaction Questionnaire.

Safety Profile

References

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{acd7760d-f31d-4d7e-8b21-2cdf496d1cc2},repository:{dam},path:{/Portal/UK/Prescribing-links/Lantus_GB_NI.pdf}}}">Prescribing Information&nbsp;UK</a> 
 &nbsp;
 &nbsp;</td>
 </tr>
 </tbody>
</table>

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{8cd02cf2-bd72-495f-b720-698ef8d3f0da},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo.pdf}}}" target="_blank">Prescribing Information UK</a> 
 &nbsp;
 &nbsp;</td>
 </tr>
 </tbody>
</table>

Lantus® (insulin glargine 100 units/mL) Prescribing Information GB

Lantus® (insulin glargine 100 units/mL) Prescribing Information NI

Toujeo® (insulin glargine 300 units/mL) Prescribing Information UK

Patient satisfaction with Toujeo (insulin glargine 300 Units/mL) in adults with T2D

<h3>Treatment persistence3</h3>
Toujeo® (insulin glargine 300 Units/mL) was associated with better treatment persistence compared with insulin glargine 100 U/mL or insulin detemir in people with T2D.
The treatment persistence and hospitalisation retrospective analysis identified 181,263 people with T2D, newly treated with insulin in 2016-2017. The study used prescription claims data from the Système National des Données de Santé, a French administrative healthcare database.3
Persistence was defined as remaining on any basal insulin or on the same insulin without discontinuation from the index date to the last prescription. A therapy was deemed discontinued when it was interrupted for a period of 6 months.3

Treatment persistence with basal insulin in adults with T2D

<h3>Hospitalisation3</h3>
Overall, a low number of episodes of hospitalised hypoglycaemia‡&nbsp;were observed in this study regardless of treatment.
The treatment persistence and hospitalisation retrospective analysis identified 181,263&nbsp;people with T2D, newly treated with insulin in 2016-2017. The study used prescription claims data from the Système National des Données de Santé, a French administrative healthcare database.3
Persistence was defined as remaining on any basal insulin or on the same insulin without discontinuation from the index date to the last prescription. A therapy was deemed discontinued when it was interrupted for a period of 6 months.3&nbsp;
‡Hospitalisations for severe hypoglycaemia and associated diagnoses were identified with ICD 10 codes.3

Hospitalisation rates with basal insulin in adults with T2D

<h3>Addition of Toujeo® to GLP-1 RA was associated with significantly improved glycaemic control.9</h3>
DELIVER-G real-world retrospective analysis.
A real-world retrospective analysis in insulin-naïve adults with T2D inadequately controlled on GLP‑1 RA with or without oral antidiabetic drugs (N=271).9
DELIVER-G was a retrospective analysis of 271 people with Type 2 diabetes receiving GLP‑1 RA therapy who were insulin‑naive prior to subsequent treatment intensification with Toujeo® (insulin glargine 300 U/mL). DELIVER‑G analysed data from a large US electronic medical record data source (IBM® Explorys).9

Toujeo (insulin glargine 300 Units/mL) in addition to GLP1-RA

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

This website is for healthcare professionals only.

Welcome to BP Sanofi Campus

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Welcome to CSU Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are about to leave Sanofi campus website.

You are about to leave Campus.sanofi/uk.

Images from <a>iStockphoto.com</a>, Fotolia.de, <c>gettyimages.de</c>, <d>pexels.com</d> and <e>photocase.de</e> were used for our websites.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch.

Would you also like to receive future messages and updates about Beyfortus?

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your QFITLIA Representative or receive updates about QFITLIA. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v6.0) - Date of Preparation: April 2024

Welcome to Sanofi Campus UK

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

Password

Confirm password

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Articles

Head to Head Studies

Head to Head Studies

What is Pompe disease?

Burden of Influenza

Multiple Sclerosis

Patient satisfaction with Toujeo (insulin glargine 300 Units/mL) in adults with T2D

Treatment persistence with basal insulin in adults with T2D

Hospitalisation rates with basal insulin in adults with T2D

Toujeo (insulin glargine 300 Units/mL) in addition to GLP1-RA